The World Health Organization WHO now completely advises against the use of the drug remdesivir against covid-19.
A new review of the antiviral drug has not been able to show that it alleviates the disease.
Early studies suggested that remdesivir could lead to a shorter course of the disease.
The drug has therefore become part of the treatment for patients with covid-19, also in Sweden.
In October ordered EU 500,000 doses worth just over SEK 10 billion.
But a month ago, after clinical studies, the WHO concluded that remdesivir has little or no effect on covid-19.
Now a WHO panel that draws up international guidelines has come to the same conclusion and advises against the drug, reports the news agency Reuters.
According to a review, there is no “evidence that strap divisions improve the odds of things that are valuable to patients, such as reduced mortality, need for a respirator, time to recover”, writes the WHO panel.
It has reviewed four international studies in which 7,000 randomly selected hospitalized patients with covid-19 were examined.
Remdesivir must be given intravenously, and the panel therefore concludes that the handling and treatment is too expensive and complex in terms of what you get out of the medicine.
The WHO’s recommendation is not binding and the panel would like to see more evaluative studies of remdesivir. The drug has been approved as a treatment for covid-19 in over 50 countries.
Source: ICELAND NEWS